Precision oncology strategy in cetuximab-resistant ERRFI1-mutant colon cancer: case report of disease progression on afatinib

Olesya Kuznetsova; Alexandra Lebedeva; Alexandra Kavun; Ekaterina Belova; Mikhail Fedyanin; Vladislav Mileyko; Maxim Ivanov; Dmitry Nosov

Precision oncology strategy in cetuximab-resistant ERRFI1-mutant colon cancer: case report of disease progression on afatinib

Am J Transl Res. 2023 Sep 15;15(9):5785-5790. eCollection 2023.

Authors

Olesya Kuznetsova^{1

2}, Alexandra Lebedeva¹, Alexandra Kavun¹, Ekaterina Belova^{1

3}, Mikhail Fedyanin^{2

4

5}, Vladislav Mileyko¹, Maxim Ivanov^{1

6}, Dmitry Nosov⁷

Affiliations

¹ OncoAtlas LLC 119049 Moscow, Russia.
² N.N. Blokhin Russian Cancer Research Center 115478 Moscow, Russia.
³ Lomonosov Moscow State University 119991 Moscow, Russia.
⁴ State Budgetary Institution of Health Care of The City of Moscow "Moscow Multidisciplinary Clinical Center Kommunarka" of The Department of Health of The City of Moscow 142770 Moscow, Russia.
⁵ Federal State Budgetary Institution "National Medical and Surgical Center Named After N.I. Pirogov" of The Ministry of Health of The Russian Federation 105203 Moscow, Russia.
⁶ Moscow Institute of Physics and Technology 141701 Dolgoprudny, Russia.
⁷ The Central Clinical Hospital of The Administrative Directorate of The President of The Russian Federation 121359 Moscow, Russia.

PMID: 37854204
PMCID: PMC10579037

Abstract

Despite the existence of effective first and second line therapy options for patients with colorectal cancer, heavily treated patients have limited additional therapies. Genomic profiling is a promising tool for guiding subsequent treatment selection. Here, we describe the results of treating a colorectal cancer patient with molecularly-matched therapy based on the results of genomic profiling. The patient received a combination of afatinib and bevacizumab due to the presence of ERRFI1 variant. To our knowledge, this is the first report on the effect of EGFR inhibitors in patients with ERRFI1-altered RAS/BRAF wild-type colorectal adenocarcinoma.

Keywords: Colorectal cancer; EGFR TKI therapy; ERRFI1 mutation; molecular tumor board; precision medicine.

Publication types

Case Reports